In vivo examination of 188Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer

Nuclear Medicine and Biology

Volumn 36, Issue 4, 2009, Pages 355-361

  Chen, Kuo Ting ^a   Lee, Te Wei ^b   Lo, Jem Mau ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

Author keywords

188Re(I) tricarbonyl ion; 188Re, radioimmunotherapy; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTIDINE; RADIOPHARMACEUTICAL AGENT; RHENIUM 188; RHENIUM 188 (IODINE) TRICARBONYL ION; SERUM ALBUMIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG STABILITY; DRUG UPTAKE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RECEPTOR, ERBB-2; RHENIUM; STAINING AND LABELING; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 67349263521     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.01.006     Document Type: Article

References (13)

1. Goldenberg D.M. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 43 (2002) 693-713
2. Nahta R., and Esteva F.J. Herceptin: mechanisms of action and resistance. Cancer Lett 232 (2006) 123-138
3. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W., et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421 (2003) 756-760
4. Plosker G.L., and Keam S.J. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs 66 (2006) 449-475
5. Smith-Jones P.M., Solit D.B., Akhurst T., Afroze F., Rosen N., and Larson S.M. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 22 (2004) 701-706
6. 111In-DTPA-trastuzumab. Br J Pharmacol 143 (2004) 99-106
7. 99mTc tricarbonyl ion. Appl Radiat Isot 66 (2008) 340-345
8. 111In-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol 32 (2005) 51-58
9. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 5 (2004) 292-302
10. + and synthesis of tailor-made bifunctional ligand systems. Bioconjug Chem 13 (2002) 750-756
11. Budman D.R., Tai J., and Calabra A. Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer lines in vitro. Breast Cancer Res Treat 104 (2007) 93-101
12. Lin W.Y., Tsai S.C., Hsieh B.T., Lee T.W., Ting G., and Wang S.J. Evaluation of three rhenium-188 candidates for intravascular radiation therapy with liquid-filled balloons to prevent restenosis. J Nucl Cardiol 7 (2000) 37-42
13. 188Re-herceptin. Nucl Med Biol 32 (2005) 59-65